© 2005-2012 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.
Using the drop-down menu below, read about highlighted scientific news from ASCO's Annual Meetings since 2002. You can select a specific year and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
The 2013 ASCO Annual Meeting is set for May 31-June 4, with research news beginning to be released on May 15 at 6pm Eastern. Additional research will be released each day of the meeting.
To read these summaries categorized into a yearly newsletter, you can also review Cancer Advances: News for Patients from the ASCO Annual Meeting.
Don’t forget to check out audio podcasts and videos about this news, as well. And, in addition to the highlighted studies below, thousands of scientific abstracts are released each year at the ASCO Annual Meeting. To search the entire collection of meeting abstracts, visit ASCO's website.
A new survey of primary care doctors in Wisconsin shows they are less likely to refer patients with advanced lung cancer to an oncologist than they are to refer patients with advanced breast cancer. This difference was seen despite the fact that most doctors surveyed said that the type and stage of a patient's cancer did not influence how strongly they encouraged patients to seek treatment.
Patients age 65 and older with early-stage lung cancer can benefit from adjuvant chemotherapy (chemotherapy after surgery) and do not experience more side effects when compared with younger patients, according to the results of a new study.
A phase III clinical trial from the Women's Intervention Nutrition Study (WINS) found for the first time that eating a lower-fat diet lowers the risk of recurrence (return of the cancer) in postmenopausal women with early stage breast cancer.
A report from the Childhood Cancer Survivor Study (CCSS) shows that adult survivors of childhood cancer have five times the risk of developing moderate to severe health problems compared with their healthy siblings.
In a new study of people with stage III colon cancer, doctors from the Cancer and Leukemia Group B (CALGB) research group found that taking aspirin regularly lowered the risk of recurrence (return of the cancer) and death by approximately 50%.
A new study shows that one quarter of people undergoing surgery for stomach cancer have the recommended number of lymph nodes removed, that this number varies widely by geographic region, and that adequate lymph node removal is related to people surviving this cancer.
People with stage III, and often stage II, colorectal cancer are given adjuvant chemotherapy (chemotherapy after surgery), to lower the risk that the cancer will return. Two reports from large phase III clinical trials evaluate the benefit of adjuvant chemotherapy in colon cancer.
A new survey from the LIVESTRONG Foundation (LAF) of 1,020 cancer survivors (ages 18 to 75) shows that nearly half feel their nonmedical needs, such as emotional distress, financial issues, and sexual side effects, are not being met.
Results of a new study show that raloxifene (Evista) is associated with lowering the risk of developing uterine (endometrial) cancer by 50%. Raloxifene is a selective estrogen receptor modulator (SERM) used to treat osteoporosis (thinning of the bones) and may lower the risk of breast cancer.
The first phase III clinical trial to test adjuvant chemotherapy (chemotherapy after surgery) with gemcitabine (Gemzar) for people with operable pancreatic cancer (cancer that can be surgically removed) shows that this treatment nearly doubles the amount of time it takes for the cancer to return.